GLAXO2,858.00

Glaxosmithkline Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersPFIZERABBOTINDIAMEDANTAANTHEMAJANTPHARMIPCALABGLENMARKBIOCONMcap ₹48,417 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
GLAXO
FY26
PFIZER
FY26
ABBOTINDIA
FY26
MEDANTA
FY26
Peer
Median
Valuation — at last close
P/E52.42×70.35×70.35× -25%
P/B21.19×9.83×9.83× +116%
EV/EBITDA35.08×43.75×43.75× -20%
Market Cap₹48,417 Cr₹39,148 Cr₹39,148 Cr +24%
Growth
Revenue CAGR 3Y5.53%1.29%9.01%17.85%9.01% -39%
Revenue CAGR 5Y3.62%2.39%9.96%6.18% -41%
Net Income CAGR 3Y19.26%5.01%17.80%19.33%17.80% +8%
Revenue YoY (latest Q)16.55%26.50%26.50% -38%
Net Income YoY (latest Q)15.69%-1.09%-1.09% +1539%
Profitability
EBITDA Margin34.26%35.88%27.31%20.84%27.31% +25%
Net Income Margin27.11%28.67%22.40%12.56%22.40% +21%
Return on Common Equity45.34%17.19%32.51%13.97%17.19% +164%
Return on Capital Employed48.84%19.71%36.14%13.20%19.71% +148%
Return on Assets23.96%14.68%23.87%9.38%14.68% +63%
Credit & Quality
Total Debt/Equity0.00×0.00×0.30×0.15× -100%
Interest Coverage455.22×89.28×72.67×8.80×72.67× +526%
Scale — latest FY
Revenue / Total Income₹3,822 Cr₹2,520 Cr₹6,929 Cr₹4,410 Cr₹4,410 Cr -13%
Net Income₹1,036 Cr₹722 Cr₹1,552 Cr₹554 Cr₹722 Cr +43%
Total Assets₹4,324 Cr₹4,922 Cr₹6,502 Cr₹5,905 Cr₹5,905 Cr -27%
EPS₹54.52₹0₹20.71₹10.36 +427%
Book Value per Share₹134.86₹148.29₹148.29 -9%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.